The breakthrough oral therapy, SoviHep, a generic version of sofosbuvir, which will provide treatment to more than 10 million patients who suffer from hepatitis C in India, has been launched by Indian drugmaker the Zydus Cadila. Shares of parent company Cadila Healthcare (BSE: 532321) surged 8.13% to 1,715 rupees on the Bombay Stock Exchange following the news.
US biotech major Gilead Sciences (Nasdaq: GILD) had signed a non-exclusive licensing agreement with Zydus and other generic drugmakers which will allow the manufacture of sofosbuvir (trade name Sovaldi) and the fixed-dose combination of ledipasvir/sofosbuvir (trade name Harvoni) for distribution in 91 countries including India. The therapy will be marketed by the specialty division of the group, Zydus Heptiza.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze